SITE014-0280

SITE014 (NLD) › SITE014-0280

SITE014-0280

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2026-08-03

enrolled

AEs

1

Serious

0

Dropout signal

–

Adverse events

1

Grade 2 Diarrhoea — outcome: UNKNOWN; onset 2023-02-12 (study day 2); relationship: NOT RELATED

moderate assessed

Data queries

1

AE Diarrhoea (grade 2) for SITE014-0280 has onset 2026-08-19, 1 d before first dose on 2026-08-20. Confirm onset date or record as pre-treatment.

onset_on[Diarrhoea 2026-08-19] open